Project Grant R01DK149542
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $100,228 to The Regents of The University of Colorado, doing business as University of Colorado-Denver, on December 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a network-based computational framework analyzing diet-microbe-host metabolic interactions. The funded work develops a systems-level model integrating genomic, microbiome, metabolomic, and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $127,206 to The Washington University on April 5, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research investigates Prevotella copri-mediated effects of dietary glycan supplementation on microbial community and host metabolism in the context of treating childhood undernutrition. The work builds on clinical trial evidence that microbiota-directed complementary...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded North Carolina State University $738,169 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate methanogen-bacterial syntrophy and its role in digestive health. The research examines interdomain syntrophic partnerships between methanogenic archaea and bacteria in the human microbiome, with focus on how dysfunction in these relationships drives...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Colorado State University $119,536 on May 6, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to assess contextual factors influencing implementation of a Type 2 diabetes nutrition education curriculum in American Indian and Alaska Native-serving healthcare and community-based organizations. The award funds implementation science research applying the Consolidated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Children's Hospital $831,433 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supporting research to redefine the biogeography and function of food proteins in human health and disease. The project establishes first principles of the food-host interactome by developing systematic approaches to map the transit, transformation, and tissue...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beckman Research Institute of The City of Hope $280,232 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research on gut-fat crosstalk in metabolic regulation. The award supports basic and translational research investigating intestinal mTOR signaling and its effects on white adipose tissue browning, glucose homeostasis, and energy metabolism....
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Duke University $612,587 on March 18, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the mechanisms by which the microbiome regulates postnatal growth and lipid metabolism in extremely preterm infants. The research addresses growth failure in extremely preterm infants, a condition independently associated with adverse neurodevelopmental outcomes. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Colorado (University of Colorado-Denver) $248,965 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds a project grant (R00DK136503) investigating pancreatic fat and volume as metabolic risk factors in childhood, leveraging the longitudinal Healthy Start Study cohort of approximately 1,400 mother-child pairs in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Leland Stanford Junior University $782,886 on February 18, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on obesity control through an appetite-suppressing peptide. The research addresses the urgent need for new metabolies, including obesity and associated metabolic disorders. Work is performed in Palo Alto, California with a period of...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded California Institute of Technology $661,126 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Listing Project Grant R01DK149061). The award funds bacterial metatranscriptomics research aimed at resolving contributions of host and microbial pathways to human health and disease. Tissue-associated microbes play fundamental roles in shaping host...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Colorado State University $775,317 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on August 20, 2026. The research project investigates the role of fecal metabolites in infant growth and overweight risk during complementary feeding (the period from approximately five to twenty-four months when infants consume foods beyond breastmilk or formula). The work aims to elucidate how complementary feeding influences gut microbiota composition and fecal metabolites, and how these metabolites mediate infant growth and body composition changes. The study employs germ-free mice models to assess the biological relevance of dietary, microbial, and host-derived metabolites to host physiology during this critical developmental window. Performance occurs in Fort Collins, Colorado. The period of performance runs through May 31, 2030. The award supports basic and clinical research aligned with NIDDK's programmatic areas in nutrition, obesity, metabolic diseases, and digestive health, advancing understanding of prevention and treatment of metabolic syndrome and obesity in adolescence and adulthood.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $775.3k | 8/19/26 |